SIHUAN PHARM (00460.HK): Two aesthetics products approved in HK
- PCL was approved by China's National Medical Products Administration in April 2025 to correct moderate to severe nasolabial folds.
NewTimeSpace News: On 20 October 2026, Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) announced that a polycaprolactone microsphere facial filler (PCL) and a sodium hyaluronate composite solution (FL) for injection, both developed and made by its Meiyan Space Biological Technology (Jilin) Co., Ltd. unit, have been approved for sale in Hong Kong. PCL was cleared in three vial sizes from 0.5 mL to 2.0 mL, and FL in six sizes from 0.5 mL to 3.0 mL plus a 5 mL box.
PCL, a regenerative filler whose gel carrier fills facial hollows immediately before the microspheres induce tissue regeneration, was approved in China in April 2025 for moderate to severe nasolabial folds. FL, the first L-carnosine composite solution skin booster for direct facial use in China, is cleared there in 12 sizes of 0.5 mL to 5 mL for superficial dermal injection. The approvals are the group's first aesthetics registrations in Hong Kong.
- SIHUAN PHARM (00460.HK): Dongyan skin booster gets five new specs in China
- SIHUAN PHARM (00460.HK): Five New Specifications of Skin Booster Dongyan Approved for Marketing by NMPA
- SIHUAN PHARM (00460.HK): Repurchases 10 million shares for about HKD 8.111 million; H1 net profit up 221% year on year
- SIHUAN PHARM(00460.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 224.7 million, YoY increase of 119%
- SIHUAN PHARM (00460.HK): Miao Guili resigns as executive director and CFO, Che Yuxuan appointed non-executive director and Song Xiaomi appointed CFO
